Psychedelika in der Psychiatrie – Entwicklungen und die Stellung in Deutschland
暂无分享,去创建一个
G. Gründer | S. Borgwardt | U. Herwig | G. Koller | Lea Mertens | Sergio Pérez Rosal | Andrea Jungaberle
[1] A. Ströhle,et al. Methodological Challenges in Psychedelic Drug Trials:Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression (EPIsoDE) – Rationale and Study Design , 2022, Neuroscience Applied.
[2] M. Liechti,et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects , 2022, Neuropsychopharmacology.
[3] G. Gründer,et al. [Are psychedelics fast acting antidepressant agents?] , 2022, Der Nervenarzt.
[4] C. Schmitz,et al. Sind Psychedelika schnell wirksame Antidepressiva? , 2022, Der Nervenarzt.
[5] S. Borgwardt,et al. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants , 2022, Psychopharmacology.
[6] D. Araujo,et al. Ayahuasca for the Treatment of Depression. , 2021, Current topics in behavioral neurosciences.
[7] Christopher M. Jones,et al. Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults. , 2021, JAMA psychiatry.
[8] G. Gründer,et al. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future , 2021, Pharmacopsychiatry.
[9] Jennifer M. Mitchell,et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study , 2021, Nature Medicine.
[10] D. Nutt,et al. Trial of Psilocybin versus Escitalopram for Depression. , 2021, The New England journal of medicine.
[11] J. Rucker,et al. Psilocybin and MDMA for the treatment of trauma-related psychopathology , 2021, International review of psychiatry.
[12] M. Boldrini,et al. How COVID-19 Affects the Brain. , 2021, JAMA psychiatry.
[13] Elizabeth M. Nielson,et al. Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research , 2021, Frontiers in Psychiatry.
[14] Matthew W. Johnson,et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder , 2020, JAMA psychiatry.
[15] S. Borgwardt,et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects , 2020, Neuropsychopharmacology.
[16] C. Grob,et al. Psychedelic medicine: safety and ethical concerns. , 2020, The lancet. Psychiatry.
[17] F. Vollenweider,et al. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders , 2020, Nature Reviews Neuroscience.
[18] R. Krause,et al. The Yale Manual for Psilocybin-Assisted Therapy of Depression (using Acceptance and Commitment Therapy as a Therapeutic Frame) , 2020 .
[19] E. Vermetten,et al. Reviewing the Potential of Psychedelics for the Treatment of PTSD , 2020, The international journal of neuropsychopharmacology.
[20] G. Gründer,et al. Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance , 2020, Frontiers in Psychiatry.
[21] D. Nutt,et al. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression , 2020, Journal of psychopharmacology.
[22] Alan K. Davis,et al. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. , 2020, Journal of contextual behavioral science.
[23] F. Vollenweider,et al. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat , 2019, Scientific Reports.
[24] Nicole Strauss,et al. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy , 2019, Journal of psychoactive drugs.
[25] S. Dursun,et al. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness , 2019, Current neuropharmacology.
[26] Robin L. Carhart-Harris,et al. How do psychedelics work? , 2019, Current opinion in psychiatry.
[27] M. Scheidegger,et al. Positive psychology in the investigation of psychedelics and entactogens: A critical review , 2018, Neuropharmacology.
[28] Jaime E. C. Hallak,et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews , 2018, Expert review of clinical pharmacology.
[29] T. Schmidt,et al. The Altered States Database: Psychometric Data of Altered States of Consciousness , 2018, Front. Psychol..
[30] T. Passie. The early use of MDMA (‘Ecstasy’) in psychotherapy (1977–1985) , 2018 .
[31] S. Borgwardt,et al. Altered network hub connectivity after acute LSD administration , 2018, NeuroImage: Clinical.
[32] D. Nutt,et al. Psychiatry & the psychedelic drugs. Past, present & future , 2017, Neuropharmacology.
[33] T. Passie,et al. MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). , 2018, Drug testing and analysis.
[34] S. Borgwardt,et al. Increased thalamic resting‐state connectivity as a core driver of LSD‐induced hallucinations , 2017, Acta psychiatrica Scandinavica.
[35] J. Gallinat,et al. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. , 2017, Fortschritte der Neurologie-Psychiatrie.
[36] M. Frye,et al. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.
[37] S. Borgwardt,et al. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects , 2017, Translational Psychiatry.
[38] J. Gallinat,et al. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. , 2017, Fortschritte der Neurologie-Psychiatrie.
[39] D. De Gregorio,et al. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology , 2016, International journal of molecular sciences.
[40] James Rucker,et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.
[41] Kevin Murphy,et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging , 2016, Proceedings of the National Academy of Sciences.
[42] F. Vollenweider,et al. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers , 2015, Biological Psychiatry.
[43] Sidarta Ribeiro,et al. The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network , 2015, PloS one.
[44] R. Strassman,et al. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.
[45] T. Brewerton,et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study , 2013, Journal of psychopharmacology.
[46] Richard G. Wise,et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.
[47] Michael Kometer,et al. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.
[48] A Dittrich,et al. The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans , 1998, Pharmacopsychiatry.
[49] D. Nichols,et al. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. , 1986, Journal of psychoactive drugs.
[50] C. Smith. A new adjunct to the treatment of alcoholism: the hallucinogenic drugs. , 1958, Quarterly journal of studies on alcohol.
[51] R. Sandison,et al. Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. , 1957, The Journal of mental science.
[52] C. Savage. Lysergic acid diethylamide; a clinical-psychological study. , 1952, The American journal of psychiatry.
[53] A. K. Busch,et al. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. , 1950, Diseases of the nervous system.
[54] L. Lewin. Phantastica : die betäubenden und erregenden Genussmittel; für Ärzte und Nichtärzte , 1927 .
[55] K. Beringer. Der Meskalinrausche seine Geschichte und Erscheinungsweise , 1927 .